{"id":"W2923453543","doi":"10.1200/jco.18.02403","title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":616,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Ibrutinib; Medicine; Vincristine; Internal medicine; Diffuse large B-cell lymphoma; Rituximab; Population; CHOP; Hazard ratio; Cyclophosphamide; Gastroenterology; Oncology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004221828,0.0003028114,0.00491922,0.0002164259,0.00003356191,0.00001538975,0.0001337159,0.000476534,0.0000924944],"category_scores_gemma":[0.001266513,0.0002017132,0.0006560002,0.0001309702,0.0003291288,0.000125512,0.0001298769,0.0004105036,0.00001251837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001893338,"about_ca_system_score_gemma":0.001014327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009312084,"about_ca_topic_score_gemma":0.00001995605,"domain_scores_codex":[0.994207,0.0006494886,0.003937433,0.0003789082,0.0004307862,0.0003964098],"domain_scores_gemma":[0.9917858,0.004674289,0.00253877,0.000271558,0.0002459055,0.0004836365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8507441,0.1054558,0.0255649,0.0001537392,0.0003019497,0.001112216,0.0002454925,4.276998e-7,0.0001593129,0.00003811615,0.0007288209,0.01549502],"study_design_scores_gemma":[0.9567341,0.01888002,0.01667021,0.0002416454,0.000936233,0.0003272273,0.0001270149,0.0004647571,0.0005363064,0.00005966,0.00486553,0.0001572777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914711,0.00197169,0.00002405538,0.0009888334,0.001039956,0.00151769,0.00002414865,0.000006271807,0.00295624],"genre_scores_gemma":[0.9924,0.004825103,0.001066521,0.0007958569,0.0004330933,0.00002223665,0.00001003549,0.00002454642,0.0004226132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.10599,"threshold_uncertainty_score":0.8225627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03015399178565479,"score_gpt":0.3882991784214436,"score_spread":0.3581451866357888,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}